FINNENCE ▪ THE WIRE FILE
THE WIRE · № 55474
Company■ Unclear/unknown
New Phase 3 trial: Study of Velaglucerase Beta ERT in Children With Gaucher Disease — CANbridge Life Sciences Ltd.
KINDCompany
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-09-29 12:00 UTC
LAST UPDATE2026-09-29 12:00 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
A tiny 10-patient pediatric Gaucher trial is minimal commercial news for a small sponsor.
Niche rare-disease program advances
CATALYST TO WATCH
Trial start and enrollment
MAIN RISK
Very small enrollment limits significance
FULL DISPATCH
Sponsor: CANbridge Life Sciences Ltd.; Status: Not Yet Recruiting; Conditions: Gaucher Disease, Gaucher Disease Type 1, Gaucher Disease Type 3; Interventions: Velaglucerase beta; Enrollment: 10 (estimated); First posted: 2026-09-29; NCT: NCT07847411
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
New Phase 3 trial: A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity — Pfizer2026-09-29 12:00 UTC
New Phase 3 trial: A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity — Pfizer2026-09-29 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: A Study to Assess the Efficacy and Safety of Afimkibart for Induction Therapy in Participants With Moderately to Severely Active Ulcerative Colitis — Hoffmann-La Roche2026-09-29 12:00 UTC
New Phase 3 trial: A Study to Assess the Efficacy and Safety of Afimkibart for Induction Therapy in Participants With Moderately to Severely Active Ulcerative Colitis — Hoffmann-La Roche2026-09-29 12:00 UTC
→CORRELATIONshares Healthcare
Phase 3 results posted: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer — Seagen Inc.2026-09-29 12:00 UTC
Phase 3 results posted: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer — Seagen Inc.2026-09-29 12:00 UTC
→CORRELATIONshares Healthcare
Phase 3 results posted: Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia — Otsuka Pharmaceutical Development & Commercialization, Inc.2026-09-29 12:00 UTC
Phase 3 results posted: Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia — Otsuka Pharmaceutical Development & Commercialization, Inc.2026-09-29 12:00 UTC
→CORRELATIONshares Healthcare
Phase 3 results posted: A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age — ModernaTX, Inc.2026-09-29 12:00 UTC
Phase 3 results posted: A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age — ModernaTX, Inc.2026-09-29 12:00 UTC
→CORRELATIONshares Healthcare
Another proposed mega merger: HealthPartners, Essentia Health boards approve plan to combine organizations2026-09-29 15:50 UTC
Another proposed mega merger: HealthPartners, Essentia Health boards approve plan to combine organizations2026-09-29 15:50 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.